Malaga Cove Capital LLC Increases Stock Position in Repligen Co. (NASDAQ:RGEN)

Malaga Cove Capital LLC increased its position in Repligen Co. (NASDAQ:RGEN) by 78.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 4,458 shares of the biotechnology company’s stock after buying an additional 1,961 shares during the quarter. Malaga Cove Capital LLC’s holdings in Repligen were worth $802,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RGEN. Benjamin F. Edwards & Company Inc. boosted its stake in shares of Repligen by 152.1% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 242 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 146 shares during the period. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen during the fourth quarter worth $965,000. Natixis Advisors L.P. raised its stake in Repligen by 27.4% during the fourth quarter. Natixis Advisors L.P. now owns 36,727 shares of the biotechnology company’s stock worth $6,603,000 after acquiring an additional 7,892 shares during the period. New York Life Investment Management LLC lifted its holdings in shares of Repligen by 6.8% in the 4th quarter. New York Life Investment Management LLC now owns 5,904 shares of the biotechnology company’s stock worth $1,062,000 after purchasing an additional 375 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in Repligen by 9.5% in the fourth quarter. Victory Capital Management Inc. now owns 21,271 shares of the biotechnology company’s stock valued at $3,825,000 after buying an additional 1,851 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ RGEN traded up $0.74 during midday trading on Friday, reaching $167.05. The company’s stock had a trading volume of 454,984 shares, compared to its average volume of 538,521. The company has a market cap of $9.33 billion, a price-to-earnings ratio of 668.23, a price-to-earnings-growth ratio of 5.46 and a beta of 1.03. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The company has a current ratio of 6.35, a quick ratio of 5.75 and a debt-to-equity ratio of 0.26. The company has a 50 day moving average price of $180.81 and a 200 day moving average price of $174.09.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.28 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.01). The company had revenue of $151.31 million during the quarter, compared to analyst estimates of $150.06 million. Repligen had a net margin of 2.44% and a return on equity of 3.95%. The company’s revenue for the quarter was down 17.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.64 EPS. On average, equities research analysts expect that Repligen Co. will post 1.46 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. reduced their target price on shares of Repligen from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Thursday. KeyCorp boosted their price objective on Repligen from $210.00 to $220.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Finally, Stifel Nicolaus lifted their target price on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $197.75.

Insider Buying and Selling

In other Repligen news, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the transaction, the director now owns 87,367 shares of the company’s stock, valued at approximately $16,892,409.45. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, Director Karen A. Dawes sold 1,000 shares of Repligen stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $193.35, for a total transaction of $193,350.00. Following the completion of the sale, the director now owns 87,367 shares of the company’s stock, valued at $16,892,409.45. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, COO James Bylund sold 4,373 shares of the company’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the transaction, the chief operating officer now directly owns 14,135 shares in the company, valued at $2,799,860.80. The disclosure for this sale can be found here. In the last ninety days, insiders sold 25,597 shares of company stock valued at $5,039,532. Corporate insiders own 1.20% of the company’s stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.